FGF7 Protein

FGF7 Protein

Overview

FGF7, commonly known as Keratinocyte Growth Factor (KGF), is a secreted signaling protein belonging to the fibroblast growth factor (FGF) family. The FGF7 gene encodes a 194-amino acid precursor that is proteolytically processed to generate the mature 163-amino acid protein with a molecular weight of approximately 19 kilodaltons. As a member of the FGF7 subfamily, FGF7 functions as a paracrine signaling molecule, meaning it is secreted by one cell type to exert effects on neighboring target cells. Structurally, FGF7 contains the characteristic FGF core domain with a β-trefoil fold that enables high-affinity binding to its cognate receptor, FGFR2 isoform IIIb (also called KGFR). The protein exhibits tissue-specific expression patterns, with primary production in fibroblasts, mesenchymal cells, and immune cells, while target cells expressing FGFR2IIIb are predominantly epithelial in origin. However, emerging evidence demonstrates that FGF7 also exerts significant effects on neural cells, making it increasingly relevant to neurodegeneration research.

Function and Biology

FGF7 Protein

Overview

FGF7, commonly known as Keratinocyte Growth Factor (KGF), is a secreted signaling protein belonging to the fibroblast growth factor (FGF) family. The FGF7 gene encodes a 194-amino acid precursor that is proteolytically processed to generate the mature 163-amino acid protein with a molecular weight of approximately 19 kilodaltons. As a member of the FGF7 subfamily, FGF7 functions as a paracrine signaling molecule, meaning it is secreted by one cell type to exert effects on neighboring target cells. Structurally, FGF7 contains the characteristic FGF core domain with a β-trefoil fold that enables high-affinity binding to its cognate receptor, FGFR2 isoform IIIb (also called KGFR). The protein exhibits tissue-specific expression patterns, with primary production in fibroblasts, mesenchymal cells, and immune cells, while target cells expressing FGFR2IIIb are predominantly epithelial in origin. However, emerging evidence demonstrates that FGF7 also exerts significant effects on neural cells, making it increasingly relevant to neurodegeneration research.

Function and Biology

FGF7 operates as a ligand in the FGF signaling cascade, initiating cellular responses through receptor tyrosine kinase activation. Upon secretion, FGF7 binds with high affinity to heparan sulfate proteoglycans (HSPGs) present on cell surfaces and in the extracellular matrix, which stabilizes the ligand and facilitates its interaction with FGFR2IIIb. This ligand-receptor engagement triggers receptor dimerization and autophosphorylation of tyrosine residues in the intracellular kinase domain. Activated FGFR2 recruits and phosphorylates adaptor proteins including FRS2α, which nucleates signaling complexes that activate downstream effector pathways, particularly the mitogen-activated protein kinase (MAPK) cascade and phosphatidylinositol 3-kinase (PI3K)/AKT pathway. These cascades culminate in altered gene expression programs, protein synthesis, and metabolic shifts favoring cell proliferation, differentiation, and survival. In epithelial tissues, FGF7 is classically recognized as a mitogenic and anti-apoptotic factor promoting wound healing and tissue regeneration. Beyond epithelial biology, FGF7 also modulates immune cell function, stimulating activation and proliferation of various leukocyte populations, thereby influencing inflammatory responses through both direct and indirect mechanisms.

Role in Neurodegeneration

Growing evidence implicates FGF7 in neuroprotective processes relevant to multiple neurodegenerative conditions. In Alzheimer's disease models, FGF7 signaling has been shown to enhance neuronal survival through PI3K/AKT-dependent pathways and reduce amyloid-beta accumulation through modulation of neuroinflammation. Studies demonstrate that FGF7 can suppress microglial activation and reduce pro-inflammatory cytokine production, thereby limiting neuroinflammatory damage that accelerates neuronal degeneration. In Parkinson's disease contexts, FGF7 exhibits neuroprotective effects against dopaminergic neurotoxicity through multiple mechanisms including enhanced mitochondrial function, reduced oxidative stress, and activation of survival signaling cascades. Research in ALS models indicates that FGF7 can support motor neuron survival and attenuate glial-mediated neurotoxicity. The protein's role in regulating glial cell populations, particularly oligodendrocytes and astrocytes, further contributes to its neuroprotective potential by promoting myelin integrity and providing metabolic support to vulnerable neurons.

Molecular Mechanisms

FGF7-mediated neuroprotection operates through coordinated activation of survival pathways and suppression of degenerative cascades. The MAPK/ERK pathway enhances expression of anti-apoptotic proteins including BCL2 family members, while PI3K/AKT activation phosphorylates and inactivates pro-apoptotic factors like BAD and FoxO transcription factors. Additionally, FGF7 signaling activates JAK/STAT pathways that regulate inflammatory gene expression in glial cells. The protein modulates reactive oxygen species production through upregulation of antioxidant enzymes and enhancement of mitochondrial electron transport efficiency. FGF7 also influences autophagy-lysosomal pathways through mTOR signaling, facilitating clearance of protein aggregates characteristic of neurodegenerative pathology.

Clinical and Research Significance

FGF7 represents a promising therapeutic candidate for neurodegenerative diseases, with potential applications in neuroprotective intervention strategies. Recombinant FGF7 administration or gene therapy approaches targeting FGF7 upregulation are under investigation for Alzheimer's disease, Parkinson's disease, and ALS. Understanding FGF7 biology may inform development of small-molecule FGFR2 agonists with improved bioavailability for CNS applications.

Related Entities

• **FG